Back to News index
Reaction to Competition and Markets Authority (CMA) investigation into alleged anti-competitive agreements - consultation on commitments
Following the update by the CMA on August 14th, 2019, Warwick Smith, Director General of Medicines UK, said: "Competition between suppliers of essentially the same medicine is what drives value for the NHS from generic medicines. We condemn any anti-competitive behaviour which undermines competition and thus reduces the benefits to the NHS and to patients of the use of generic medicines."